BRAF and MEK inhibition in melanoma patients enables reprogramming of tumor infiltrating lymphocytes

BACKGROUND: Combined inhibition of BRAF/MEK is an established therapy for melanoma. In addition to its canonical mode of action, effects of BRAF/MEK inhibitors on antitumor immune responses are emerging. Thus, we investigated the effect of these on adaptive immune responses. PATIENTS, METHODS AND RE...

Descripción completa

Detalles Bibliográficos
Autores principales: Peiffer, Lukas, Farahpour, Farnoush, Sriram, Ashwin, Spassova, Ivelina, Hoffmann, Daniel, Kubat, Linda, Stoitzner, Patrizia, Gambichler, Thilo, Sucker, Antje, Ugurel, Selma, Schadendorf, Dirk, Becker, Jürgen C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2020
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8139931/
https://www.ncbi.nlm.nih.gov/pubmed/33275172
http://dx.doi.org/10.1007/s00262-020-02804-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8139931/
https://www.ncbi.nlm.nih.gov/pubmed/33275172
http://dx.doi.org/10.1007/s00262-020-02804-4

Ejemplares similares